Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1991): Kleier RS, Arch Dermatol 127, 1361
Rash (sic) (1–10%)
(2007): Arif H+, Neurology 68(20), 1701
(2006): Ajith C+, Int J Dermatol 45(12), 1452
(2001): Aihara M+, Br J Dermatol 144(6), 1231
(1999): Mamon HJ+, Epilepsia 40, 341 (with cranial radiation)
(1987): Maguire JH+, Br J Clin Pharmacol 24, 554
Reticular hyperplasia
Rhinophyma
(2000): Jaramillo MJ+, Br J Plast Surg 53(6), 521
Scleroderma
Sezary syndrome
(1994): Doyle MF+, Acta Hematol 92, 204
Stevens–Johnson syndrome (14%)
(2006): Powell N+, Postgrad Med J 82(968), e10
(2005): Lin MS+, Intern Med J 35(3), 188
(2005): Mockenhaupt M+, Neurology 64(7), 1134
(2004): Gomez-Criado MS+, Rev Neurol 38(11), 1056
(2004): Scheinfeld N, Expert Opin Drug Saf 3(6), 655
(2004): Singh G+, J Neurol Neurosurg Psychiatry 75(2), 331 (1
case)
(2003): Camartin C+, Schweiz Rundsch Med Prax 92(9), 393
(2001): Eralp Y+, Am J Clin Oncol 24(4), 347
(2000): Madnani NA, Mumbai, India (from Internet)
(observation)
(1999): DeToledo JC+, Ther Drug Monit 21(1), 137
(1999): Khafaga YM+, Acta Oncol 38, 111 (with cranial
irradiation)
(1999): Ruble R+, CNS Drugs 12, 215
(1999): Rzany B+, Lancet 353, 2190
(1996): Cockey G+, Am J Clin Oncol 19, 32 (with irradiation of
brain)
(1996): Leong KP+, Asian Pac J Allergy Immunol 14, 65 (14.3%)
(1995): Borg M+, Australas Radiol 39, 42 (with irradiation of
brain)
(1995): Cockey GH+, Am J Clin Oncol 19, 32
(1995): Wolkenstein P+, Arch Dermatol 131, 544
(1994): Marti J+, An Med Interna (Spanish) 11, 621
(1993): Janinis J+, Eur J Cancer 29A, 478 (with cranial irradiation)
(1993): Leenutaphong V+, Int J Dermatol 32, 428
(1993): Schlienger RG+, Schweiz Rundsch Med Prax (German)
82, 888
(1992): Tone T+, JDermatol19, 27
(1989): Kelly DF+, Neurosurgery 25, 976
(1988): Delattre JY+, Neurology 38, 194 (with cranial irradiation)
(1988): Shear NH+, J Clin Invest 82, 1826
(1985): Burge SM+, JAmAcadDermatol13, 665
(1985): de Rego JA+, Hillside J Clin Psychiatry 7, 141
(1985): Maiche A+, Lancet 2, 45 (with radiation therapy)
(1985): Tucker MS+, J Am Osteopath Assoc 85(8), 511
(1982): Oles KS+, Clin Pharm 1, 565
(1980): Livingston S+, Am Fam Physician 22(2), 123
toxic dermatitis (sic)
Toxic epidermal necrolysis (2%)
(2006): Rodriguez G+, JAmAcadDermatol55(5), S96 (mother
and fetus)
(2005): Lin MS+, Intern Med J 35(3), 188
(2004): Aguiar D+, J Neurooncol 66(3), 345
(2004): Gomez-Criado MS+, Rev Neurol 38(11), 1056
(2004): Scheinfeld N, Expert Opin Drug Saf 3(6), 655
(2002): Schummer W+, J Neurosurg Anesthesiol 14(3), 229
(2002): ten Holder SM+, Ann Pharmacother 36(1), 130
(2000): Cohen AD+, Isr Med Assoc J 1, 95 (2 patients)
(2000): Moussala M+, JFrOphtalmol(French) 23, 229
(1999): Cohen AD+, Isr Med Assoc J 1, 95 (2 cases)
(1999): Egan CA+, JAmAcadDermatol40, 458 (3 cases)
(1999): Ruble R+, CNS Drugs 12, 215
(1999): Rzany B+, Lancet 353, 2190
(1997): Jester BA+, American Academy of Dermatology Meeting
(SF), Poster #163
PHENYTOIN 437
(1997): Redondo Bellon P, Rev Neurol 25, S309
(1997): Sapadin A+, American Academy of Dermatology
Meeting (SF), Poster #111 (with radiation)
(1996): Creamer JD+, Clin Exp Dermatol 21, 116
(1996): Frangogiannis NG+, South Med J 89, 1001
(1996): Leong KP+, Asian Pac J Allergy Immunol 14, 65 (2.4%)
(1995): Pion IA+, NEnglJMed333, 1609
(1993): Janinis J+, Eur J Cancer 29A, 478
(1993): Leenutaphong V+, Int J Dermatol 32, 428
(1992): Tone T+, JDermatol19, 27
(1991): Rowe JE+, Int J Dermatol 30, 747
(1989): Kelly DF+, Neurosurgery 25, 976
(1989): Renfro L+, Int J Dermatol 28, 441
(1988): Dreyfuss DA+, Ann Plast Surg 20, 146
(1987): Birchall N+, JAmAcadDermatol16, 368
(1985): Burge SM+, JAmAcadDermatol13, 665
(1985): Muhar U, Pediatr Dermatology 3, 54
(1985): Sherertz EF+, JAmAcadDermatol12, 178
(1984): Chan HL, JAmAcadDermatol10, 973
(1984): Smith DA+, JAmAcadDermatol10, 106 (followed by
universal depigmentation)
(1983): Schmidt D+, Epilepsia 24, 440 (fatal)
(1982): Peterson KA+, Md State Med J 31, 53
(1981): Spechler SJ+, AnnInternMed95, 455
Urticaria
(2004): Singh G+, J Neurol Neurosurg Psychiatry 75(2), 331 (1
case)
(1995): Rodriguez-Castellanos M+, Arch Dermatol 131, 620
Vasculitis (2%)
(2004): Scheinfeld N, Expert Opin Drug Saf 3(6), 655
(2002): ten Holder SM+, Ann Pharmacother 36(1), 130
(1999): Holt P, NZMedJ112, 100
(1996): Leong KP+, Asian Pac J Allergy Immunol 14, 65 (2.4%)
(1996): Parry RG+, NephrolDialTransplant11, 357
(1993): Drory VE+, Clin Neuropharmacol 16, 19 (passim)
(1984): Smith DA+, JAmAcadDermatol10(1), 106
(1983): Yermakov VM+, Hum Pathol 14, 182
Verrucae
(1998): Kayal JD+, Cutis 61, 101
Mucosal
Gingival hyperplasia/hypertrophy (>10%)
(2004): Scheinfeld N, Expert Opin Drug 3(6), 655
(2004): Soga Y+, Life Sci 74(7), 827
(2003): Jaiarj N, JMassDentSoc52(3), 16
(2003): Takada K+, J Periodontal Res 38(5), 477
(2002): Prasad VN+, JIndianSocPedodPrevDent20(2), 73
(2001): Brunet L+, Eur J Clin Invest 31(9), 781
(2001): Uzel MI+, JPeriodontol72(7), 921
(2000): Sharma S+, NEnglJMed342(5), 325
(1999): Kamali F+, J Periodontal Res 34, 145
(1999): Trevisol-Bittencourt PC+, Arq Neuropsiquiatr
57(3B), 784
(1999): Wood WH, San Jose, CA (from Internet) (observation)
(1998): Desai P+, J Can Dent Assoc 64, 263
(1998): Garzino-Demo P+, Minerva Somatol (Italian) 47, 387
(1998): Mattson JS+, J Am Dent Assoc 129, 78
(1998): Meraw SJ+, Mayo Clin Proc 73, 1196
(1997): Casetta I+, Neuroepidemiology 16(6), 296 (40%)
(1997): Huang JS+, KaohsiungJMedSci13(3), 141
(1997): Iacopino AM+, JPeriodontol68, 73
(1997): Mattioli A, Minerva Stomatol (Italian) 46, 525
(1997): Newland JR, JGtHouseDentSoc69, 3
(1997): Silverstein LH+, Gen Dent 45, 371
(1996): Ball DE+, JPeriodontol67(6), 597
(1996): Hayakawa I+, Quintessence Int 27, 235
(1996): Saito K+, JPeriodontolRes31, 545
(1996): Seymour RA+, J Clin Periodontol 23(3 Pt 1), 165
(1995): McLaughlin WS+, J Clin Periodontol 22(12), 942
(1995): Moghadam BKH+, Cutis 56, 46 (passim)